GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Paxman AB (FRA:B0F) » Definitions » Debt-to-EBITDA

Paxman AB (FRA:B0F) Debt-to-EBITDA : 0.36 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Paxman AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Paxman AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.99 Mil. Paxman AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.23 Mil. Paxman AB's annualized EBITDA for the quarter that ended in Dec. 2023 was €3.40 Mil. Paxman AB's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.36.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Paxman AB's Debt-to-EBITDA or its related term are showing as below:

FRA:B0F' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -141.94   Med: 0.43   Max: 5.93
Current: 0.43

During the past 7 years, the highest Debt-to-EBITDA Ratio of Paxman AB was 5.93. The lowest was -141.94. And the median was 0.43.

FRA:B0F's Debt-to-EBITDA is ranked better than
71.76% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs FRA:B0F: 0.43

Paxman AB Debt-to-EBITDA Historical Data

The historical data trend for Paxman AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paxman AB Debt-to-EBITDA Chart

Paxman AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 4.43 -46.93 5.92 1.05 0.43

Paxman AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 1.52 0.70 0.36 0.36

Competitive Comparison of Paxman AB's Debt-to-EBITDA

For the Medical Devices subindustry, Paxman AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paxman AB's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Paxman AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Paxman AB's Debt-to-EBITDA falls into.



Paxman AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Paxman AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.987 + 0.226) / 2.793
=0.43

Paxman AB's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.987 + 0.226) / 3.4
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Paxman AB  (FRA:B0F) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Paxman AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Paxman AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Paxman AB (FRA:B0F) Business Description

Traded in Other Exchanges
Address
Pirgatan 13, Karlshamn, SWE, SE-374 35
Paxman AB is a Sweden based company engages in the development of PAXMAN Scalp Cooling System that is used to minimize hair loss in connection with chemotherapy treatment. The company offers a stand-alone, mobile electric cooling unit, which is a liquid-based cooling system that cools down the patient's scalp through the silicone hat. Geographically the company markets its product to Great Britain, Scandinavian countries, the Netherlands, Belgium, and Australia.

Paxman AB (FRA:B0F) Headlines

No Headlines